Pfizer Drug Combination to Treat Colorectal Cancer Cleared by FDA

MT Newswires Live
2024-12-21

Pfizer (PFE) Friday said the US Food and Drug Administration approved a combination of its Braftovi cancer drug with Eli Lilly's (LLY) Erbitux medication and three other chemotherapies to treat patients with metastatic colorectal cancer with a BRAF V600E mutation as detected through an FDA-approved test.

The regulatory approval followed phase 3 study. Initial data showed patients in the active arm of the trial had an objective response rate of 61%, compared with a 40% rate in chemotherapy, with or without bevacizumab, Pfizer said.

Median duration of response for the Braftovi patients was 13.9 months, compared with 11.1 months in the other arm, the company said, adding testing is ongoing, with complete trial data to be presented at future medical meetings.

Pfizer shares recently were more than 2% higher.

Price: 26.38, Change: +0.61, Percent Change: +2.37

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10